Clinical trial · Interventional
Axillary Reverse Mapping
ARM: Axillary Reverse Mapping
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
It has been hypothesized that the proximity of the anatomic locations of the arm lymphatic drainage system to the breast lymphatic system in the axilla put the arm lymphatics at risk for disruption during a sentinel lymph node biopsy (SLNB) and/or axillary lymph node dissection (ALND). Therefore, mapping the drainage of the arm in addition to the drainage of the breast during the procedure would potentially decrease the incidence of arm lymphatic disruption and subsequent development of lymphedema while providing adequate axillary breast nodes needed for staging.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Axillary lymph node dissection | Procedure | — | UNRESOLVED |
| Injection of isotope | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- Sentinel lymph node biopsy
- description
- During surgery, 1.0 mCi of technetium-99m sulfur colloid will be injected into sub-dermal subareolar aspect of the affected breast. The KUMC Nuclear Medicine Department will be responsible for performing the injection of the isotope and dilution of the isotope using saline to a final volume of 4.0 ml or less.
- interventionNames
- Procedure: Injection of isotope
- type
- OTHER
- label
- Axillary lymph node biopsy
- interventionNames
- Procedure: Axillary lymph node dissection
Primary outcomes (1)
- measure
- Assess lymphedema rates
- timeFrame
- Four Years
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 - 100 years old * Not pregnant or breastfeeding * Diagnosis of breast cancer requiring LN evaluation for ipsilateral or contralateral breast or prophylactic mastectomy * Willing participation after obtaining informed consent Exclusion Criteria: * \< 18 or \> 100 years of age * Pregnant or breastfeeding * Blue dye allergy * Cosmetic allergy * History of primary lymphedema * Prior breast augmentation
References
Publications (0)
Data not yet available